Table 1.
Comparison of demographic and clinical characteristics between persons with insufficient and adequate 25(OH)D.
| Characteristic | Inadequate 25(OH)D N=45 | Adequate 25(OH)D N=40 | P value |
|---|---|---|---|
| Demographics | |||
| Age | 38 (33–45) | 36 (31–43) | 0.4 |
| Gender (female) | 14 (31) | 12 (30) | 0.9 |
| BMI | 21.5 (20.0–22.8) | 21.5 (19.0–24.3) | 1.0 |
| Disease stage | |||
| Stage 4 KS | 23 (51) | 17 (43) | 0.4 |
| ACTG T1 | 38 (84) | 33 (83) | 0.8 |
| Baseline laboratory | |||
| Hemoglobin | 11 (9.4–11.9) | 11.3 (10.3–12.6) | 0.2 |
| CD4+ lymphocyte count | 117 (76–208) | 141 (70–222) | 0.5 |
| HIV-1 VL (log) | 4.7 (4.3–5.0) | 4.5 (3.9–4.9) | 0.04 |
| HHV-8 plasma VL (log) | 2.9 (2.1–3.5) | 2.8 (1.8–3.4) | 0.4 |
| HHV-8 PBMC VL (log) | 3.2 (2.4–4.4) | 3.5 (2.5–4.1) | 0.8 |
| 96 week changea | |||
| Increase in CD4+ lymphocyte count | 85 (21–291) | 105 (30–202) | 0.8 |
| Decrease in HIV-1 VL (log) | 1.9 (1.3–2.4) | 1.3 (0.8–1.9) | 0.04 |
| Decrease in HHV-8 plasma VL (log) | 0.5 (0–1.5) | 0.4 (0–1.5) | 0.8 |
| Decrease in HHV-8 PBMC VL (log) | 0.9 (−0.4–2.3) | 1.0 (0–2.0) | 0.9 |
Median and intraquartile range or number and percentage are reported for each variable; BMI: body mass index; KS: Kaposi Sarcoma; ACTG T1: AIDS Clinical Trials Group Tumor 1 Staging; VL: viral load; HHV-8: Human Herpes Virus 8; PBMC: peripheral blood mononuclear cells.
a
week 96 or last available results